stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) Net income
Vericel Corporation's net income for fiscal 2025 was $16.5M, up 59.4% from $10.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $33.3M. Over the past ten years it has ranged from −$19.6M (fiscal 2016) to $16.5M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 3 consecutive fiscal years. Vericel Corporation ranks 42nd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $16.5M | 59.41% |
| FY2024 | $10.4M | — |
| FY2023 | −$3.2M | — |
| FY2022 | −$16.7M | — |
| FY2021 | −$7.5M | — |
| FY2020 | $2.9M | — |
| FY2019 | −$9.7M | — |
| FY2018 | −$8.1M | — |
| FY2017 | −$17.3M | — |
| FY2016 | −$19.6M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $14.2M | 541.93% |
| Jun 2026 | $2.2M | — |
| Mar 2026 | −$6.3M | — |
| Dec 2025 | $23.2M | 358.08% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $314.3M |
| ADMA ADMA Biologics Inc compare | $182.4M |
| VCEL Vericel Corporation | $33.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$61.7M |
| PHVS Pharvaris N.V. compare | −$193.1M |
| IMNM Immunome, Inc. compare | −$254.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| VERA Vera Therapeutics, Inc. compare | −$401.9M |
| BHVN Biohaven Ltd. compare | −$542.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on VCEL
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement